Compare EVH & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVH | TECX |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 667.0M | 618.9M |
| IPO Year | 2015 | 2018 |
| Metric | EVH | TECX |
|---|---|---|
| Price | $3.39 | $22.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 9 |
| Target Price | $5.75 | ★ $76.63 |
| AVG Volume (30 Days) | ★ 1.5M | 187.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.70 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $907,957,000.00 | N/A |
| Revenue This Year | $40.46 | N/A |
| Revenue Next Year | $25.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $14.62 |
| 52 Week High | $8.46 | $39.53 |
| Indicator | EVH | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 32.24 | 26.51 |
| Support Level | $2.53 | $20.52 |
| Resistance Level | $3.68 | $31.39 |
| Average True Range (ATR) | 0.18 | 1.43 |
| MACD | -0.02 | -0.33 |
| Stochastic Oscillator | 3.12 | 7.02 |
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.